$1.77 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 31 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 175.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $107,105,000 | – | 10,895,773 | +100.0% | 6.07% | – |
| PHVS | New | PHARVARIS N.V. | $88,993,000 | – | 3,180,601 | +100.0% | 5.04% | – |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $59,796,000 | -34.8% | 3,695,667 | +7.3% | 3.39% | -41.2% |
| SLDB | Buy | SOLID BIOSCIENCES INC | $43,852,000 | -18.1% | 7,929,918 | +12.3% | 2.48% | -26.1% |
| SVRA | Buy | SAVARA INC | $24,175,000 | +309.9% | 11,622,598 | +126.6% | 1.37% | +270.0% |
| New | MARINUS PHARMACEUTICALS INC | $22,153,000 | – | 1,431,058 | +100.0% | 1.26% | – | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $18,249,000 | +72.2% | 2,119,540 | +28.6% | 1.03% | +55.5% |
| BLUE | New | BLUEBIRD BIO, INC. | $16,226,000 | – | 538,179 | +100.0% | 0.92% | – |
| RACB | New | RESEARCH ALLIANCE CORP II | $10,250,000 | – | 1,000,000 | +100.0% | 0.58% | – |
| ARYD | New | ARYA SCIENCES ACQUISITION CORP IVcl a | $7,331,000 | – | 700,000 | +100.0% | 0.42% | – |
| OMEG | New | OMEGA ALPHA SPACcl a | $3,960,000 | – | 400,000 | +100.0% | 0.22% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.